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To the Editor,
The debate on what tube is most accurate for glucose 
estimation has been ongoing for several years. Fasting 
plasma glucose (FPG) estimation accuracy is central in 
the diagnosis of diabetes [1]. Having a tube with antico-
agulant that preserves glucose concentration immediately 
is pivotal for correct classifications. The guideline rec-
ommends the sample tube be immediately placed in an 
ice-slurry and the plasma be separated from cells within 
30 min [2]. The guideline is not only impractical, but it is 
also difficult to enforce for compliance if the collection is 
off-site. Laboratories do not always receive these or other 
samples in timely manner, within 10–15 min to centrifuge 
and analyse samples.
The transport/storage temperature can be variable, 
analytical equipment may not be available due to techni-
cal issues, and even if all the above criteria are optimised, 
cellular activity continues to alter the glucose concentra-
tion. We have looked at almost all the alternatives on tube 
appropriateness and we did not find a definite solution 
[3]. Terumo had the Venosafe Glycaemia tube, which was 
reported to increase the number of patients with abnormal 
FPG >7.0 mmol/L from 17.8% to 23.3% [4]. This tube is no 
longer on the market. What is also of concern is the actual 
number of false low-glucose results in samples routinely 
collected in standard serum and lithium heparin tubes 
as part of chemistry profiles where pre-analytical factors 
vary and glucose consumption would be significant.
Greiner has released the new FC Mix Glucose tube 
with the dry anticoagulants combination. We under-
took a study to evaluate the stability of glucose in this 
tube. The study was divided in two parts. The first part 
involved recruiting participants with consent, which 
was approved by the Princess Alexandra Hospital Ethics 
Committee. Blood was collected in the following tubes: 
lithium heparin tube (Ref 456083), NaF/K oxalate tube 
(Ref. 454061) and the new FC Mix tube (Ref. 454511) 
(Greiner Bio-one, Kremsmuster, Austria) by a phleboto-
mist without any specific order of draw. The tubes were 
centrifuged within 10  min of collection at 3000 g for 
10 min at 20 °C. There were 41 participants recruited, 35 
normal and 6 with diabetes. The reason being the most 
significant effect on glucose is at around the diagnosti-
cally important cut-off values [5]. The lithium heparin 
plasma was used as the reference sample [2], but these 
tubes were not placed in an ice slurry; intead, they were 
centrifuged within 10  min of collection then analysed 
immediately post-centrifugation along with the FC Mix 
and NaF tube for each participant. The centrifuged NaF/K 
oxalate and FC Mix tubes were stored at 23 °C (room tem-
perature; RT) and reanalysed at 2- and 4-h intervals to 
determine if the glucose concentration would change.
The second part was the stability study. In our organi-
sation, samples can be exposed to higher temperatures 
in the pre-analytical phase; hence, it is important to 
test the inhibitory ability of the FC Mix tube to preserve 
glucose concentration at various temperatures. Samples 
were collected from two volunteers in the NaF/K oxalate 
and the FC Mix tubes. A set of 10 of each tube was col-
lected, pooled and aliquoted into vials for incubation over 
0.5, 1.0, 2.0 and 4.0 h at 23 °C (RT), 2–8 °C and 37 °C. The 
zero time aliquot for each tube was immediately centri-
fuged (within 10  min of collection) and the plasma was 
aliquoted into clean tubes. The other aliquots were incu-
bated uncentrifuged for the required times, then centri-
fuged, and the plasma was aliquoted into clean tubes. The 
plasma samples were then all analysed in triplicate at the 
same time on the same analyser.
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The analysis was performed on a Beckman DxC800 
general chemistry analyser (glucose oxidase method; 
Beckman Coulter, Brea, CA, USA). The glucose method 
coefficient of variation (CV) for the two internal controls 
were QCL1 mean 4.49 mmol/L, CV 2.26% and QCL2 mean 
15.43 mmol/L CV 1.22%. The CV of QCL1 was used to deter-
mine if results would fall outside the analytical error 
(>2.3%), which would indicate that the change is due to 
glycolysis.
Statistical analysis was performed using the Microsoft 
Excel and Analyse-It statistical add-on for Microsoft Excel 
(Analyse-It, Leeds, UK). The patient comparisons were 
assessed by Passing Bablok regression correlation.
For the sample comparison study, the participants’ 
glucose range was 4.29–12.76 mmol/L. The correlation 
equations, mean glucose concentration and the mean 
differences from the lithium heparin tube for the FC Mix 
and NaF/K oxalate tubes are shown in Table 1. The results 
clearly show the FC Mix correlates much better than the 
NaF/K oxalates with lithium heparin plasma results. The 
prolonged storage (2 and 4 h) of the centrifuged tubes 
showed that both tubes maintained the change in glucose 
concentration to less than the technically allowable limit, 
preventing any analytically significant glucose decrease 
at RT. However, there is a slight decrease with the NaF/K 
oxalate samples.
The stability study results are shown in Table 2. For 
the FC Mix, the change in glucose concentration at differ-
ent storage times and temperatures was less than the tech-
nical limit (<2.3%), and no analytically significant effect 
was observed. However, with the NaF/K oxalate tube, 
glycolysis was slowest at the lowest storage temperature, 
2–8 °C, whereas it was fastest at 37 °C. Both at RT and 37 °C 
storage, the glycolysis peaks and stops at 2 h with around 
7.5% decrease. The samples stored at 2–8 °C up to 1  h 
showed a decrease, but it was less than analytical limit.
One notable observation was the plasma in the FC 
mix tube had, in about ~15% of samples, a darker brown 
appearance, giving a higher haemolytic index (HI) (mean 
HI: lithium heparin plasma, 0.05; NaF/K oxalate, 0.93; FC 
Table 1: Results of the participant (n = 41 adults) comparison study in the different Greiner tubes when compared with the lithium heparin 
plasma.
Tube type (lithium 
heparin 5.91 mmol/L 
base line value)
  Mean glucose 
concentration, 
mmol/L
  Correlation data 
(Passing Bablok)  
(CI 95% of slope)
  Mean difference in glucose 
concentration from Lithium 
heparin plasma mmol/L (%)
NaF/K oxalate
 0 h   5.86  Y=1.01x − 0.12 (−0.23 to 0.06)   −0.05 (−1.0)
 2 h   5.82  Y=1.02x − 0.18 (−0.31 to −0.05)  −0.09 (−1.6)
 4 h   5.83  Y=1.01x − 0.17 (−0.42 to −0.02)  −0.08 (−1.5)
FC Mix
 0 h   5.94  Y=1.00x + 0.04 (−0.28 to 0.17)   0.03 (0.6)
 2 h   5.93  Y=1.00x + 0.02 (−0.17 to 0.21)   0.02 (0.4)
 4 h   5.97  Y=1.02x − 0.07 (−0.07 to 0.24)   0.06 (1.0)
Table 2: Stability of glucose when stored at 23 °C (RT), 2–8 °C and 37 °C for 0.5, 1, 2 and 4 h before centrifugation.
Temperature, °C 
 
Time, hours
0 Mean 
glucose, 
mmol/L
  0.5 Mean 
glucose, 
mmol/L
  % difference  1 Mean 
glucose, 
mmol/L
  % difference  2 Mean 
glucose, 
mmol/L
  % difference  4 Mean 
glucose, 
mmol/L
  % difference
FC Mix tube
 23 (RT)   5.33  5.33  0.0  5.32  0.3  5.35  0.3  5.30  −0.6
 2–8   5.33  5.39  1.0  5.37  0.7  5.41  1.5  5.41  1.5
 37   5.33  5.34  0.1  5.29  −0.8  5.34  <0.1  5.30  −0.6
NaF/K Oxalate tube
 23 (RT)   5.19  5.00  −3.7  4.89  −5.8  5.05  −7.5  5.0  −7.8
 2–8   5.19  5.10  −1.8  5.08  −2.1  5.05  −2.8  5.00  −3.8
 37   5.19  4.91  −5.5  4.82  −7.1  4.82  −7.3  4.81  −7.3
Bold, results outside limit.
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Mix, 1.08; level of 1.0 = 0–50 mg/dL haemoglobin concen-
tration). This would most likely be directly induced by the 
anticoagulant mix and its impact on cellular membranes. 
Pasqualetti et al. reported a significant “shift to the right”, 
an increase in the median FPG results, with the Terumo 
tube [4]. In this study, the differences between the means 
were minimal. However, this shift increased with delayed 
processing of samples collected in the NaF/K oxalate 
tubes, but not to the level observed by Pasqualetti et al.
Laboratories continuing to use the NaF/K oxalate 
tube should store tubes at 2–8 °C to minimise glucose con-
sumption and improve accuracy in glucose determination. 
However, these samples should be centrifuged at least 
within that hour or immediately and continued to be stored 
at 2–8 °C until analysed if the plasma cannot be separated.
The FC Mix tube has been shown to meet the need 
for preventing immediate glucose consumption by cells, 
eliminating false decrease in glucose concentrations. In 
turn, this will allow patient diagnosis and classifications 
to be accurately determined at all times.
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